Biocon Limited — Important, 25-05-2025: General Updates

Biocon Biologics secured MHRA and European Commission approvals for YESINTEK®, its biosimilar of Ustekinumab, targeting psoriasis, psoriatic arthritis, and Crohn’s disease. This paves the way for sales across the UK, EU, and EEA, enhancing its position in the high-growth immunology segment. Clinical data supports comparable safety and efficacy to the original, positioning YESINTEK® for strong commercial uptake and revenue growth in key markets.